Signaling cross-talk in the resistance to HER family receptor targeted therapy.

ASIA unversity > 醫學暨健康學院 > 生物科技學系 > 期刊論文 > Item 310904400/86933

jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://asiair.asia.edu.tw/ir/handle/310904400/86933

题名:	Signaling cross-talk in the resistance to HER family receptor targeted therapy.
作者:	Yamaguchi, H;Yamaguchi, H.;Chang, S-S.;Chang, S-S.;Hsu, J.L.;Hsu, J.L.;洪明奇*
贡献者:	生物科技學系
日期:	2014
上传时间:	2014-11-07 06:53:06 (UTC+0)
摘要:	Epidermal growth factor receptor (EGFR) and human EGFR 2 (HER2) have an important role in the initiation and progression of various types of cancer. Inhibitors targeting these receptor tyrosine kinases are some of the most successful targeted anticancer drugs widely used for cancer treatment; however, cancer cells have mechanisms of intrinsic and acquired drug resistance that pose as major obstacles in drug efficacy. Extensive studies from both clinical and laboratory research have identified several molecular mechanisms underlying resistance. Among them is the role of signaling cross-talk between the EGFR/HER2 and other signaling pathways. In this review, we focus particularly on this signaling cross-talk at the receptor, mediator and effector levels, and further discuss alternative approaches to overcome resistance. In addition to well-recognized signaling cross-talk involved in the resistance, we also introduce the cross-talk between EGFR/HER2-mediated pathways and pathways triggered by other types of receptors, including those of the Notch, Wnt and TNFR/IKK/NF-κB pathways, and discuss the potential role of targeting this cross-talk to sensitize cells to EGFR/HER2 inhibitors.
關聯:	ONCOGENE;33(9):1073-81.
显示于类别:	[生物科技學系] 期刊論文

文件中的档案:

档案	大小	格式	浏览次数
index.html	0Kb	HTML	425	检视/开启

在ASIAIR中所有的数据项都受到原著作权保护.

数据加载中.....